Lilly Acquisition News: Recent discussions on X about Adverum Biotechnologies (ADVM) have centered on the company’s acquisition by Eli Lilly, with the tender offer expiring and 64% of shares tendered as of December 9, 2025. Many users are highlighting the deal’s terms, which include a potential value of up to $8.91 per share via contingent value rights. The merger is reportedly set to close on the same day, sparking significant attention.
Insider Trading Activity: Another hot topic on X involves recent insider transactions, with the CEO purchasing shares worth over $550,000, seen by some as a vote of confidence before the merger. However, a major shareholder’s sale of over half a million shares has raised eyebrows and fueled speculation about mixed signals. This has kept the conversation lively and dynamic.
Analyst Downgrade Impact: Posts on X also mention a downgrade by HC Wainwright, slashing their price target by 83% to $5.00 and revising earnings forecasts downward for 2025. Some users argue this reflects caution ahead of the acquisition, while others question the timing of such a bearish outlook. The debate continues to drive engagement around the stock.
Note: This discussion summary was generated from an AI condensation of post data.
Adverum Biotechnologies Insider Trading Activity
Adverum Biotechnologies insiders have traded $ADVM stock on the open market 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ADVM stock by insiders over the last 6 months:
- BRADEN MICHAEL LEONARD has made 0 purchases and 4 sales selling 1,099,446 shares for an estimated $4,608,205.
- LAURENT FISCHER (CEO, PRESIDENT AND DIRECTOR) has made 2 purchases buying 128,699 shares for an estimated $553,916 and 0 sales.
- PETER SOPARKAR (CHIEF OPERATING OFFICER) purchased 50,000 shares for an estimated $211,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Adverum Biotechnologies Hedge Fund Activity
We have seen 14 institutional investors add shares of Adverum Biotechnologies stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRANKLIN RESOURCES INC removed 1,760,056 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,784,120
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 1,008,187 shares (+94.3%) to their portfolio in Q3 2025, for an estimated $4,567,087
- PRINCIPIA WEALTH ADVISORY, LLC added 332,301 shares (+19.6%) to their portfolio in Q2 2025, for an estimated $714,447
- RENAISSANCE TECHNOLOGIES LLC removed 207,173 shares (-36.3%) from their portfolio in Q3 2025, for an estimated $938,493
- TCG CROSSOVER MANAGEMENT, LLC removed 128,308 shares (-7.1%) from their portfolio in Q3 2025, for an estimated $581,235
- BLACKROCK, INC. removed 103,091 shares (-24.9%) from their portfolio in Q3 2025, for an estimated $467,002
- GOLDMAN SACHS GROUP INC removed 94,706 shares (-19.0%) from their portfolio in Q3 2025, for an estimated $429,018
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Adverum Biotechnologies Analyst Ratings
Wall Street analysts have issued reports on $ADVM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/13/2025
- Mizuho issued a "Outperform" rating on 06/26/2025
To track analyst ratings and price targets for Adverum Biotechnologies, check out Quiver Quantitative's $ADVM forecast page.
Adverum Biotechnologies Price Targets
Multiple analysts have issued price targets for $ADVM recently. We have seen 4 analysts offer price targets for $ADVM in the last 6 months, with a median target of $8.5.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $5.0 on 11/17/2025
- Lisa Walter from RBC Capital set a target price of $4.0 on 10/28/2025
- Daniil Gataulin from Chardan Capital set a target price of $33.0 on 08/13/2025
- Graig Suvannavejh from Mizuho set a target price of $12.0 on 06/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
